TPG GP A, LLC - 22 Jan 2026 Form 4 Insider Report for Sionna Therapeutics, Inc. (SION)

Role
10%+ Owner
Signature
/s/ Martin Davidson, Chief Accounting Officer, TPG GP A, LLC (5)
Issuer symbol
SION
Transactions as of
22 Jan 2026
Net transactions value
-$10,000,000
Form type
4
Filing time
26 Jan 2026, 17:24:52 UTC
Previous filing
30 Dec 2025
Next filing
02 Feb 2026

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
TPG GP A, LLC 10%+ Owner C/O TPG INC., 301 COMMERCE STREET, SUITE 3300, FORT WORTH /s/ Martin Davidson, Chief Accounting Officer, TPG GP A, LLC (5) 26 Jan 2026 0001903793
COULTER JAMES G 10%+ Owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH /s/ Gerald Neugebauer, on behalf of James G. Coulter (5) (6) 26 Jan 2026 0001099776
WINKELRIED JON 10%+ Owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH /s/ Gerald Neugebauer, on behalf of Jon Winkelried (5) (6) 26 Jan 2026 0001366946

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SION Common Stock Sale $10,000,000 -250,000 -3.7% $40.00 6,494,962 22 Jan 2026 See Explanation of Responses F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which exercises direct or indirect control over entities that collectively hold 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC.
F2 The Rise Fund SPV GP, LLC is the general partner of each of The Rise Fund Sling, L.P., which directly holds 5,340,931 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), and The Rise Fund Sling II, L.P. (together with The Rise Fund Sling, L.P., the "TPG Funds"), which directly holds 1,154,031 shares of Common Stock.
F3 Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any
F4 Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

(5) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (6) Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.